Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3

Phase 4
Completed
Conditions
Interventions
First Posted Date
2020-06-05
Last Posted Date
2024-11-14
Lead Sponsor
Joo-Yong Hahn
Target Recruit Count
5506
Registration Number
NCT04418479
Locations
🇰🇷

Samsung Medical Center, Seoul, Korea, Republic of

Cilostazol and Endothelial Progenitor Cell

First Posted Date
2020-05-29
Last Posted Date
2020-05-29
Lead Sponsor
Gyeongsang National University Hospital
Target Recruit Count
60
Registration Number
NCT04407312

Randomised Evaluation of COVID-19 Therapy

First Posted Date
2020-05-11
Last Posted Date
2024-01-05
Lead Sponsor
University of Oxford
Target Recruit Count
70000
Registration Number
NCT04381936
Locations
🇻🇳

Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam

🇬🇭

Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana

🇮🇳

Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India

and more 4 locations

Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19

First Posted Date
2020-04-29
Last Posted Date
2020-04-29
Lead Sponsor
University of Milan
Target Recruit Count
5
Registration Number
NCT04368377
Locations
🇮🇹

L. Sacco Hospital, Milano, Lombardia, Italy

Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy

Phase 4
Completed
Conditions
Interventions
First Posted Date
2020-04-20
Last Posted Date
2022-09-26
Lead Sponsor
Duke University
Target Recruit Count
19
Registration Number
NCT04352439
Locations
🇺🇸

Sarasota Memorial HealthCare System, Sarasota, Florida, United States

🇺🇸

Duke University Hospital, Durham, North Carolina, United States

Coronavirus Response - Active Support for Hospitalised Covid-19 Patients

Phase 3
Withdrawn
Conditions
Interventions
First Posted Date
2020-04-13
Last Posted Date
2020-11-19
Lead Sponsor
London School of Hygiene and Tropical Medicine
Registration Number
NCT04343001
Locations
🇳🇬

University College Hospital, Ibadan, Oyo, Nigeria

🇵🇰

Shifa Tameer-e-Millat University, Rawalpindi, Pakistan

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2020-04-01
Last Posted Date
2020-04-01
Lead Sponsor
Inova Health Care Services
Target Recruit Count
19
Registration Number
NCT04328883
Locations
🇺🇸

Inova Fairfax Hospital, Falls Church, Virginia, United States

The Effect of Salicylate on Platelet Function in CKD (Chronic Kidney Disease) Patients Treated With Aranesp

Not Applicable
Recruiting
Conditions
Interventions
First Posted Date
2020-04-01
Last Posted Date
2024-01-25
Lead Sponsor
Zealand University Hospital
Target Recruit Count
60
Registration Number
NCT04330729
Locations
🇩🇰

Medicinsk afdeling, SUH Roskilde, Roskilde, Denmark

Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial

First Posted Date
2020-03-27
Last Posted Date
2024-01-11
Lead Sponsor
Population Health Research Institute
Target Recruit Count
6667
Registration Number
NCT04324463
Locations
🇨🇦

Niagara Health System-St. Catharine's, St. Catharines, Ontario, Canada

🇧🇷

Santa Casa de Votuporanga, Votuporanga, Sao Paulo, Brazil

🇨🇦

London Health Sciences Centre, London, Ontario, Canada

and more 63 locations
© Copyright 2024. All Rights Reserved by MedPath